Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14935681 | 1.00 | FPR2 (1.00) | FPR2AKR1B1 | |
| SCHEMBL14935439 | 0.99 | FPR2 (1.00) | FPR2AKR1B1 | |
| SCHEMBL14951275 | 0.88 | FPR2 (1.00) | FPR2AKR1B1 | |
| SCHEMBL14938341 | 0.85 | FPR2 (0.74) | FPR2AKR1B1 | |
| SCHEMBL14935374 | 0.83 | FPR2 (0.73) | FPR2 | |
| SCHEMBL14935503 | 0.82 | FPR2 (0.74) | FPR2 | |
| SCHEMBL14945852 | 0.81 | FPR2 (0.69) | FPR2 | |
| SCHEMBL14935394 | 0.81 | FPR2 (0.67) | FPR2AKR1B1 | |
| SCHEMBL14935314 | 0.79 | FPR2 (0.67) | FPR2 | |
| SCHEMBL16008139 | 0.78 | FPR2 (1.00) | FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10434112-B2 | Use of agonists of formyl peptide receptor 2 for treating dermatological diseases | ALLERGAN, INC. (US) | 2019-10-08 | — | — | US | disclosed |
| US-20170216326-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES | ALLERGAN, INC. | 2017-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170216326-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES | FPR2, FPR1, FPR3 | FPR2 1/4885AKR1B1 1894/4885 |
| US-10434112-B2 | Use of agonists of formyl peptide receptor 2 for treating dermatological diseases | FPR2, FPR1, FPR3 | FPR2 1/4885AKR1B1 1894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.